Cytotoxic synergy between flavopiridol (NSC 649890, L86-8275) and various antineoplastic agents: The importance of sequence of administration

Cancer Research

Volumn 57, Issue 16, 1997, Pages 3375-3380

  Bible, Keith C ^a,b   Kaufmann, Scott H ^a  

^a MAYO CLINIC COLLEGE OF MEDICINE   (United States)

^b MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CARMUSTINE; CISPLATIN; CYCLIN DEPENDENT KINASE INHIBITOR; CYTARABINE; DOXORUBICIN; ETOPOSIDE; FLAVOPIRIDOL; FLUOROURACIL; PACLITAXEL; TOPOTECAN;

ARTICLE; CARCINOMA CELL; CELL CYCLE G1 PHASE; CELL CYCLE G2 PHASE; CELL CYCLE S PHASE; CYTOTOXICITY; DRUG POTENTIATION; HUMAN; HUMAN CELL; LUNG NON SMALL CELL CANCER; PRIORITY JOURNAL;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; CARMUSTINE; CISPLATIN; CYCLIN-DEPENDENT KINASES; CYTARABINE; DOXORUBICIN; DRUG ADMINISTRATION SCHEDULE; DRUG SYNERGISM; ETOPOSIDE; FLAVONOIDS; FLUOROURACIL; HUMANS; LUNG NEOPLASMS; PACLITAXEL; PIPERIDINES; TUMOR STEM CELL ASSAY;

EID: 0030812207     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Hunter, T., and Pines, J. Cyclins and Cancer II. Cyclin D and CDK inhibitors come of age. Cell, 79: 573-582, 1994.
2. Sherr, C. J. Cancer cell cycles. Science (Washington DC), 274: 1672-1677, 1996.
3. Senderowicz, A. M., Headlee, D., Stinson, S., Lush, R. M., Tompkins, A., Brawley, O., Bergan, R., Figg, W. D., Smith, A., and Sausville, E. A. Phase I trial of a novel cyclin-dependent kinase inhibitor flavopiridol in patients with refractory neoplasms. Ann. Oncol., 7(Suppl. 1): 77, 1996.
4. Meijer, L. Chemical inhibitors of cyclin-dependent kinases. Trends Cell Biol., 6: 393-397, 1996.
5. Losiewicz, M. D., Carlson, B. A., Kaur, G., Sausville, E. A., and Worland, P. J. Potent inhibition of CDC2 kinase activity by the flavonoid L86-8275. Biochem. Biophys. Res. Commun., 201: 589-595, 1994.
6. 1 arrest with inhibition of cyclin-dependent kinase (CDK) 2 and CDK4 in human breast carcinoma cells. Cancer Res., 56: 2973-2978, 1996.
7. de Azevedo, W. F., Mueller-Dieckmann, H-J., Schulze-Gahmen, U., Worland, P. J., Sausville, E., and Kim, S-H. Structural basis for specificity and potency of a flavonoid inhibitor of human CDK2, a cell cycle kinase. Proc. Natl. Acad. Sci. USA, 93: 2735-2740, 1996.
8. cdc2 kinase by the flavone L86-8275 in breast carcinoma cells. Correlation with decreased H1 kinase activity. Biochem. Pharmacol., 46: 1831-1840, 1993.
9. Fisher, R. P., and Morgan, D. O. A novel cyclin associates with MO15/CDK7 to form the CDK-activating kinase. Cell, 78: 713-724, 1994.
10. Kaur, G., Stetler-Stevenson, M., Sebers, S., Worland, P., Sedlacek, H., Myers, C., Czech. J., Naik, R., and Sausville, E. Growth inhibition with reversible cell cycle arrest of carcinoma cells by flavone L86-8275. J. Natl. Cancer Inst., 84: 1736-1740, 1992.
11. Czech, J., Hoffmann, D., Naik, R., and Sedlacek, H-H. Antitumoral activity of flavone L86-8275. Int. J. Oncol., 6: 31-36, 1995.
12. Bible, K. C., and Kaufmann, S. H. Flavopiridol (NSC 649890, L86-8275): a eytotoxic flavone that induces cell death in human lung carcinoma cells. Cancer Res., 56: 4856-4861, 1996.
13. Drees, M., Dengler, W. A., Roth, T., Labonte, H., Mayo, J., Malspeis, L., Grever, M., Sausville, E. A., and Fiebig, H. H. Flavopiridol (L86-8275): selective antitumor in vitro and activity in vivo for prostate carcinoma cells. Clin. Cancer Res., 3: 273-279, 1997.
14. Parker, B. W., Senderowicz, A. M., Nieves-Neira, W., Pommier, Y., and Sausville, E. A. DNA fragmentation and apoptosis of lymphoma and prostate cancer cell lines after flavopiridol treatment. Proc. Am. Assoc. Cancer Res., 37: 398, 1996.
15. Schwartz, G. K., Farsi, K., Danso, D., Dhupar, S. K., Kelsen, D., and Spriggs, D. The protein kinase C (PKC) inhibitors UCN-01 and flavopiridol (FLAVO) significantly enhance the cytotoxic effect of chemotherapy by promoting apoptosis in gastric and breast cancer cells. Proc. Am. Soc. Clin. Oncol., 15: 501, 1996.
16. Senderowicz, A. M., Headlee, D., Stinson, S., Lush, R. M., Figg, W. D., Pluda, J., and Sausville, E. A. A Phase I trial of flavopiridol (FLA), a novel cyclin-dependent kinase inhibitor, in patients with refractory neoplasms. Proc. Am. Soc. Clin. Oncol., in press. 1997.
17. Kaufmann, S. H., Peereboom, D., Buckwalter, C. A., Svingen, P. A., Donehower, R. C., and Rowinsky, E. K. Cytotoxic effects of topotecan combined with various anticancer agents in human cancer cell lines. J. Natl. Cancer Inst., 88: 734-741, 1996.
18. Chou, T-C., and Talalay, P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv. Enzyme Regul., 22: 27-55, 1984.
19. Cheng, M. F., Chatterjee, S., and Berger, N. A. Schedule-dependent cytotoxicity of topotecan alone and in combination chemotherapy regimens. Oncol. Res., 6: 269-279, 1994.
20. Reed, E., Dabholkar, M., and Chabner, B. A. Platinum analogues. In: B. A. Chabner and D. L. Longo (eds.), Cancer Chemotherapy and Biotherapy, pp. 357-378. Philadelphia: Lippincott-Raven Publishers, 1996.